CoChat

Navigating tissue chips from development to dissemination: A pharmaceutical industry perspective

Open access
Ewart, Lorna, Fabre, Kristin, Chakilam, Ananthsrinivas, Dragan, Yvonne, Duignan, David B, Eswaraka, Jeetu, Gan, Jinping, Guzzie-Peck, Peggy, Otieno, Monicah, Jeong, Claire G, Keller, Douglas A, de Morais, Sonia M, Phillips, Jonathan A, Proctor, William, Sura, Radhakrishna, Van Vleet, Terry, Watson, David, Will, Yvonne, Tagle, Danilo, Berridge, Brian · 2017 · Experimental Biology and Medicine
Cited by 89

The DOI matches its Crossref record; 10 of the 10 references it cites were found in a registry or an index.

Abstract

Tissue chips are poised to deliver a paradigm shift in drug discovery. By emulating human physiology, these chips have the potential to increase the predictive power of preclinical modeling, which in turn will move the pharmaceutical industry closer to its aspiration of clinically relevant and ultimately animal-free drug discovery. Despite the tremendous science and innovation invested in these tissue chips, significant challenges remain to be addressed to enable their routine adoption into the industrial laboratory. This article describes the main steps that need to be taken and highlights key considerations in order to transform tissue chip technology from the hands of the innovators into those of the industrial scientists. Written by scientists from 13 pharmaceutical companies and partners at the National Institutes of Health, this article uniquely captures a consensus view on the progression strategy to facilitate and accelerate the adoption of this valuable technology. It concludes that success will be delivered by a partnership approach as well as a deep understanding of the context within which these chips will actually be used. Impact statement: The rapid pace of scientific innovation in the tissue chip (TC) field requires a cohesive partnership between innovators and end users. Near term uptake of these human-relevant platforms will fill gaps in current capabilities for assessing important properties of disposition, efficacy and safety liabilities. Similarly, these platforms could support mechanistic studies which aim to resolve challenges later in development (e.g. assessing the human relevance of a liability identified in animal studies). Building confidence that novel capabilities of TCs can address real world challenges while they themselves are being developed will accelerate their application in the discovery and development of innovative medicines. This article outlines a strategic roadmap to unite innovators and end users thus making implementation smooth and rapid. With the collective contributions from multiple international pharmaceutical companies and partners at National Institutes of Health, this article should serve as an invaluable resource to the multi-disciplinary field of TC development.

Overview

The claims and statistics of this paper haven’t been checked yet.

Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.

A few free checks a day · papers already verified open instantly · results are public

Integrity signals

Registry

Crossref · 10.1177/1535370217715441

Cites

10 of 10 references verified0 citation errors · 0 not checkable

Statistics

Verification

Claims the paper makes

The claims and statistics of this paper haven’t been checked yet.

Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.

A few free checks a day · papers already verified open instantly · results are public

Self-check

Percentages, sums and reported differences re-computed from the paper’s own numbers.

The self-check needs the paper’s full text.

Citations

Cites

Show all 10 references

Cited by

See all 89

Metadata

Authors
Ewart, L., Fabre, K., Chakilam, A., Dragan, Y., Duignan, D. B., Eswaraka, J., Gan, J., Guzzie-Peck, P., Otieno, M., Jeong, C. G., Keller, D. A., de Morais, S. M., Phillips, J. A., Proctor, W., Sura, R., Van Vleet, T., Watson, D., Will, Y., Tagle, D., & Berridge, B.
Venue
Experimental Biology and Medicine
Published
2017-06-16
Volume
242
Issue
16
Pages
1579-1585
ISSN
  • 0071-3384 (ISSN-L)
  • 1535-3702
  • 1535-3699
OpenAlex
W2626436465
Cited by
89
References
10
Type
journal article
Language
en
Open access
green

About these checks

Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.

Statistics and arithmetic are recomputed, not judged.

Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.

What counts as a claim ›How we measure confidence ›How we check this ›

Are you an author, or do you see a problem with this page? Request a review

How to cite

Cite CoChat for the checks on this page, and the paper for its own findings.

This page
CoChat. (2026). Citation check: Navigating tissue chips from development to dissemination: A pharmaceutical industry perspective. https://app.cochat.ai/papers/10.1177/1535370217715441
The paper
Ewart, L., Fabre, K., Chakilam, A., Dragan, Y., Duignan, D. B., Eswaraka, J., Gan, J., Guzzie-Peck, P., Otieno, M., Jeong, C. G., Keller, D. A., de Morais, S. M., Phillips, J. A., Proctor, W., Sura, R., Van Vleet, T., Watson, D., Will, Y., Tagle, D., & Berridge, B. (2017). Navigating tissue chips from development to dissemination: A pharmaceutical industry perspective. Experimental Biology and Medicine. https://doi.org/10.1177/1535370217715441

Data sources

Bibliographic data: Semantic Scholar, OpenAlex, Crossref.

Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).

Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.